Completed PHASE2 INTERVENTIONAL NCT00034164

Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer

A Phase IIA Multicenter Evaluation of the Safety and Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Patients With Relapsed Stage IIIB OR IV Non Small Cell Lung Cancer

Sponsor: Achieve Life Sciences

Conditions Carcinoma, Non-Small-Cell Lung

Interventions S-8184 Paclitaxel Injectable Emulsion

Updated 8 times since 2017 Last updated: Jun 2, 2009 Started: Apr 30, 2002 Primary completion: Sep 30, 2007 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Carcinoma, Non-Small-Cell Lung and is currently completed. Achieve Life Sciences leads this study, which shows 8 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Sep 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Sep 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Achieve Life Sciences

Data source: Achieve Life Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• 3 Cities, Russia